Highly infectious CJD particles lack prion protein but contain many viral-linked peptides by LC-MS/MS

Terry Kipkorir1, Sarah Tittman, Sotirios Botsios

  • 1Section of Neuropathology, Department of Surgery, Yale University Medical School, 333 Cedar St, New Haven, Connecticut, 06510.

Insights

This study purified infectious prion particles, revealing over 1,500 non-prion proteins, some with viral motifs, suggesting novel therapeutic targets for transmissible spongiform encephalopathies (TSEs) and neurodegenerative diseases.

Area of Science:

  • Neuroscience
  • Proteomics
  • Virology

Background:

  • Transmissible spongiform encephalopathies (TSEs) are linked to prion protein (PrP) conversion.
  • However, infectious TSE particles retain infectivity even without detectable PrP.
  • Proteomic analysis of non-PrP components in TSE particles is underexplored.

Purpose of the Study:

  • To identify non-PrP proteins within infectious TSE particles.
  • To characterize the composition of PrP-depleted infectious particles.
  • To explore potential viral or host factors involved in TSE pathogenesis.

Main Methods:

  • Streamlined, high-yield purification of infectious FU-CJD mouse brain particles.
  • Proteinase K (PK) treatment to remove residual PrP.
  • Mass spectrometry (LC-MS/MS) for proteomic identification of non-PrP proteins.
  • Bioinformatic analysis against environmental-viral databases.

Main Results:

  • Purified particles lacking detectable PrP retained infectivity.
  • Over 1,500 non-PrP proteins were identified, with 114 showing viral motifs.
  • Specific host proteins, including Huntingtin and retromer components, were uniquely found in sCJD samples.
  • PK treatment resulted in smaller viral-size particles (∼70S).

Conclusions:

  • Infectious TSE particles contain a substantial non-PrP proteome, potentially including viral elements.
  • Host proteins like Huntingtin and retromer-associated components may play roles in sporadic CJD (sCJD) pathogenesis.
  • Targeting retromer-vesicular trafficking could offer new therapeutic strategies for sCJD and other neurodegenerative diseases.